CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation

Journal of Autoimmunity

Volumn 35, Issue 4, 2010, Pages 424-435

  Hintermann, Edith ^a   Bayer, Monika ^a   Pfeilschifter, Josef M ^a   Luster, Andrew D ^b   Christen, Urs ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cellular trafficking; Chemokine; Hepatic fibrosis; Hepatitis; Inflammation

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; DESMIN; DYE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GRANZYME B; HEAT SHOCK PROTEIN 70; NEUTRALIZING ANTIBODY; SIRIUS RED; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE SEVERITY; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTE; LIVER FIBROSIS; LIVER INJURY; LIVER PARENCHYMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; STELLATE CELL; T LYMPHOCYTE; TH1 CELL; WILD TYPE;

ANIMALS; ANTIBODIES, BLOCKING; CARBON TETRACHLORIDE; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL10; DISEASE PROGRESSION; GRANZYMES; HEPATIC STELLATE CELLS; KILLER CELLS, NATURAL; LIVER; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CXCR3; UP-REGULATION;

EID: 77958154113     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.09.003     Document Type: Article

References (59)

1. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
2. Friedman S.L., Rockey D.C., Bissell D.M. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 2007, 45:242-249.
3. Iredale J.P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007, 117:539-548.
4. Cheung O., Sanyal A.J. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2009, 25:230-237.
5. Czaja A.J. Autoimmune liver disease. Curr Opin Gastroenterol 2009, 25:215-222.
6. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
7. Selmi C., Lleo A., Pasini S., Zuin M., Gershwin M.E. Innate immunity and primary biliary cirrhosis. Curr Mol Med 2009, 9:45-51.
8. Vergani D., Mieli-Vergani G. Autoimmune Hepatitis and PSC Connection. Clin Liver Dis 2008, 12:187-202. x.
9. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.
10. Gressner A.M., Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006, 10:76-99.
11. Svegliati-Baroni G., De Minicis S., Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008, 28:1052-1064.
12. Winau F., Quack C., Darmoise A., Kaufmann S.H. Starring stellate cells in liver immunology. Curr Opin Immunol 2008, 20:68-74.
13. Christen U., McGavern D.B., Luster A.D., von Herrath M.G., Oldstone M.B. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003, 171:6838-6845.
14. Rhode A., Pauza M.E., Barral A.M., Rodrigo E., Oldstone M.B., von Herrath M.G., et al. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 2005, 175:3516-3524.
15. Christen U., Benke D., Wolfe T., Rodrigo E., Rhode A., Hughes A.C., et al. Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest 2004, 113:74-84.
16. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002, 168:3195-3204.
17. Khan I.A., MacLean J.A., Lee F.S., Casciotti L., DeHaan E., Schwartzman J.D., et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000, 12:483-494.
18. Arai K., Liu Z.X., Lane T., Dennert G. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell Immunol 2002, 219:48-56.
19. Oo Y.H., Adams D.H. The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 2010, 34:45-54.
20. Clark-Lewis I., Mattioli I., Gong J.H., Loetscher P. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 2003, 278:289-295.
21. Kohrgruber N., Groger M., Meraner P., Kriehuber E., Petzelbauer P., Brandt S., et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol 2004, 173:6592-6602.
22. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
23. Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 2001, 81:409-418.
24. Asselah T., Bieche I., Laurendeau I., Paradis V., Vidaud D., Degott C., et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129:2064-2075.
25. Harvey C.E., Post J.J., Palladinetti P., Freeman A.J., Ffrench R.A., Kumar R.K., et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003, 74:360-369.
26. Nishioji K., Okanoue T., Itoh Y., Narumi S., Sakamoto M., Nakamura H., et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001, 123:271-279.
27. Zeremski M., Petrovic L.M., Chiriboga L., Brown Q.B., Yee H.T., Kinkhabwala M., et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008.
28. Chuang Y.H., Lian Z.X., Cheng C.M., Lan R.Y., Yang G.X., Moritoki Y., et al. Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 2005, 25:126-132.
29. Itoh Y., Morita A., Nishioji K., Fujii H., Nakamura H., Kirishima T., et al. Time course profile and cell-type-specific production of monokine induced by interferon-gamma in Concanavalin A-induced hepatic injury in mice: comparative study with interferon-inducible protein-10. Scand J Gastroenterol 2001, 36:1344-1351.
30. Koniaris L.G., Zimmers-Koniaris T., Hsiao E.C., Chavin K., Sitzmann J.V., Farber J.M. Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration. J Immunol 2001, 167:399-406.
31. Bone-Larson C.L., Hogaboam C.M., Evanhoff H., Strieter R.M., Kunkel S.L. IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J Immunol 2001, 167:7077-7083.
32. Hogaboam C.M., Bone-Larson C.L., Steinhauser M.L., Lukacs N.W., Colletti L.M., Simpson K.J., et al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. FASEB J 1999, 13:1565-1574.
33. Yoneyama H., Kai Y., Koyama J., Suzuki K., Kawachi H., Narumi S., et al. Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury. Med Mol Morphol 2007, 40:191-197.
34. Tiegs G., Hentschel J., Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992, 90:196-203.
35. Nagy L.E. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003, 228:882-890.
36. Proell V., Mikula M., Fuchs E., Mikulits W. The plasticity of p19 ARF null hepatic stellate cells and the dynamics of activation. Biochim Biophys Acta 2005, 1744:76-87.
37. Christen U., Wolfe T., Mohrle U., Hughes A.C., Rodrigo E., Green E.A., et al. A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol 2001, 166:7023-7032.
38. Winau F., Hegasy G., Weiskirchen R., Weber S., Cassan C., Sieling P.A., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007, 26:117-129.
39. Gao B., Radaeva S., Jeong W.I. Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 2007, 1:173-180.
40. Notas G., Kisseleva T., Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009, 130:16-26.
41. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
42. Ren X., Kennedy A., Colletti L.M. CXC chemokine expression after stimulation with interferon-gamma in primary rat hepatocytes in culture. Shock 2002, 17:513-520.
43. Bonacchi A., Romagnani P., Romanelli R.G., Efsen E., Annunziato F., Lasagni L., et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001, 276:9945-9954.
44. Holt A.P., Haughton E.L., Lalor P.F., Filer A., Buckley C.D., Adams D.H. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009, 136:705-714.
45. Fife B.T., Kennedy K.J., Paniagua M.C., Lukacs N.W., Kunkel S.L., Luster A.D., et al. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001, 166:7617-7624.
46. Liu M.T., Keirstead H.S., Lane T.E. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 2001, 167:4091-4097.
47. Shields P.L., Morland C.M., Salmon M., Qin S., Hubscher S.G., Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 1999, 163:6236-6243.
48. Tamaru M., Nishioji K., Kobayashi Y., Watanabe Y., Itoh Y., Okanoue T., et al. Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine 2000, 12:299-308.
49. Christen U., von Herrath M.G. Cytokines and chemokines in virus-induced autoimmunity. Adv Exp Med Biol 2003, 520:203-220.
50. Christen U., von Herrath M.G. IP-10 and type 1 diabetes: a question of time and location. Autoimmunity 2004, 37:273-282.
51. Novobrantseva T.I., Majeau G.R., Amatucci A., Kogan S., Brenner I., Casola S., et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 2005, 115:3072-3082.
52. Kakimi K., Lane T.E., Wieland S., Asensio V.C., Campbell I.L., Chisari F.V., et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001, 194:1755-1766.
53. Wald O., Weiss I.D., Wald H., Shoham H., Bar-Shavit Y., Beider K., et al. IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 2006, 176:4716-4729.
54. Sauty A., Colvin R.A., Wagner L., Rochat S., Spertini F., Luster A.D. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 2001, 167:7084-7093.
55. Melhem A., Muhanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006, 45:60-71.
56. Radaeva S., Wang L., Radaev S., Jeong W.I., Park O., Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol 2007, 293:G809-G816.
57. Wasmuth H.E., Lammert F., Zaldivar M.M., Weiskirchen R., Hellerbrand C., Scholten D., et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 137:309-319. 319e1-319e3.
58. Tager A.M., Kradin R.L., LaCamera P., Bercury S.D., Campanella G.S., Leary C.P., et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004, 31:395-404.
59. Holdener M., Hintermann E., Bayer M., Rhode A., Rodrigo E., Hintereder G., et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008, 205:1409-1422.